{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:52:07Z","timestamp":1793710327108,"version":"4.6.1"},"reference-count":102,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1136\/bjophthalmol-2016-309034","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T22:23:12Z","timestamp":1472509392000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":399,"title":["Metastatic disease from uveal melanoma: treatment options and future prospects"],"prefix":"10.1136","volume":"101","author":[{"given":"Richard D","family":"Carvajal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongalp","family":"Tezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2016-309034-1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-3","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov"},{"key":"key-10.1136\/bjophthalmol-2016-309034-4","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U.S","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-5","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","article-title":"Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients","volume":"119","author":"Damato","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key-10.1136\/bjophthalmol-2016-309034-7","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/112067219600600423","article-title":"Dysplastic nevi are a risk factor for uveal melanoma","volume":"6","author":"Hammer","year":"1996","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-9","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2005.04.020","article-title":"Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis","volume":"112","author":"Shah","year":"2005","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaophthalmol.2013.129","article-title":"Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes","volume":"131","author":"Shields","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archopht.124.1.54","article-title":"The association between host susceptibility factors and uveal melanoma: a meta-analysis","volume":"124","author":"Weis","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-12","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"key-10.1136\/bjophthalmol-2016-309034-13","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"key-10.1136\/bjophthalmol-2016-309034-14","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-10-2076","article-title":"Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification","volume":"16","author":"Damato","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ijc.11558","article-title":"Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution","volume":"108","author":"H\u00f6glund","year":"2004","journal-title":"Int J Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-16","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bjc.2012.54","article-title":"Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study","volume":"106","author":"Thomas","year":"2012","journal-title":"Br J Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bjophthalmol-2013-303867","article-title":"Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma","volume":"98","author":"Cassoux","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2016-309034-19","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1167\/iovs.08-2145","article-title":"Oncogenic mutations in GNAQ occur early in uveal melanoma","volume":"49","author":"Onken","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2016-309034-20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"key-10.1136\/bjophthalmol-2016-309034-21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","article-title":"AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models","volume":"6","author":"Davies","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key-10.1136\/bjophthalmol-2016-309034-22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2012.43.0454","article-title":"KRAS mutation: should we test for it, and does it matter?","volume":"31","author":"Roberts","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1755-148X.2012.00979.x","article-title":"The genetics of uveal melanoma: an emerging framework for targeted therapy","volume":"25","author":"Harbour","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-25","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"key-10.1136\/bjophthalmol-2016-309034-26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat Genet"},{"key":"key-10.1136\/bjophthalmol-2016-309034-27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"key":"key-10.1136\/bjophthalmol-2016-309034-28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2012.11.036","article-title":"Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival","volume":"182","author":"Lake","year":"2013","journal-title":"Am J Pathol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/eye.2012.126","article-title":"Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture","volume":"26","author":"Damato","year":"2012","journal-title":"Eye (Lond)"},{"key":"key-10.1136\/bjophthalmol-2016-309034-30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.5858\/133.8.1197","article-title":"The 7th Edition AJCC staging system for eye cancer: an international language for ophthalmic oncology","volume":"133","author":"Finger","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"key-10.1136\/bjophthalmol-2016-309034-31","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Opthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2016-309034-32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000367715","article-title":"Adjuvant therapy of uveal melanoma: current status","volume":"1","author":"Triozzi","year":"2015","journal-title":"Ocul Oncol Pathol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-33","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-35","doi-asserted-by":"crossref","first-page":"Abstract 9074","DOI":"10.1200\/jco.2014.32.15_suppl.9074","article-title":"Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma","volume":"32","author":"Postow","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-37","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","article-title":"Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma","volume":"119","author":"Onken","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-38","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1538-7445.AM2015-4262","article-title":"PRAME as a biomarker for a new molecular subclass of uveal melanoma","volume":"75","author":"Field","year":"2015","journal-title":"Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-40","unstructured":"Nathan P , Cohen V , Coupland S , et al. Uveal Melanoma National Guidelines. 2015. http:\/\/melanomafocus.com\/activities-2\/um-guidelines-resources\/"},{"issue":"7","key":"key-10.1136\/bjophthalmol-2016-309034-41","doi-asserted-by":"crossref","first-page":"vii86","DOI":"10.1093\/annonc\/mds229","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Dummer","year":"2012","journal-title":"Ann Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-42","unstructured":"NCCN. NCCN Practice Guidelines in Oncology Melanoma (version 4.2014). 2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/melanoma.pdf"},{"key":"key-10.1136\/bjophthalmol-2016-309034-43","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"key-10.1136\/bjophthalmol-2016-309034-44","doi-asserted-by":"crossref","first-page":"Abstract 9031","DOI":"10.1200\/jco.2013.31.15_suppl.9031","article-title":"Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma","volume":"31","author":"Sacco","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-45","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2147\/OPTH.S28863","article-title":"Current and emerging treatment options for uveal melanoma","volume":"7","author":"Pereira","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","article-title":"Treatment of metastatic uveal melanoma with intravenous fotemustine","volume":"23","author":"Spagnolo","year":"2013","journal-title":"Melanoma Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-47","doi-asserted-by":"crossref","first-page":"Abstract 3060","DOI":"10.1200\/jco.2014.32.15_suppl.3060","article-title":"Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients","volume":"32","author":"Deo","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-48","doi-asserted-by":"crossref","first-page":"Abstract 8549","DOI":"10.1200\/jco.2012.30.15_suppl.8549","article-title":"Ipilimumab in the treatment of uveal melanoma: the Memorial Sloan-Kettering Cancer Center experience","volume":"30","author":"Khan","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-49","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-50","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-51","doi-asserted-by":"crossref","first-page":"Abstract 9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial","volume":"32","author":"Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-52","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS ONE"},{"key":"key-10.1136\/bjophthalmol-2016-309034-53","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"key-10.1136\/bjophthalmol-2016-309034-54","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2016-309034-55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-56","doi-asserted-by":"crossref","first-page":"Abstract 9010","DOI":"10.1200\/jco.2015.33.15_suppl.9010","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma","volume":"33","author":"Kottschade","year":"2015","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-57","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"Cruz","year":"2003","journal-title":"Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-58","first-page":"775","article-title":"Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma","volume":"8","author":"Swaika","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"key-10.1136\/bjophthalmol-2016-309034-59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1060028013513009","article-title":"Dabrafenib therapy for advanced melanoma","volume":"48","author":"Trinh","year":"2014","journal-title":"Ann Pharmacother"},{"key":"key-10.1136\/bjophthalmol-2016-309034-60","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-61","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-62","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-010-1323-z","article-title":"Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice","volume":"67","author":"Denton","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-63","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-11-3086","article-title":"Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance","volume":"18","author":"Ambrosini","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12885-015-1470-z","article-title":"Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)","volume":"15","author":"Carvajal","year":"2015","journal-title":"BMC Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-65","article-title":"SUMIT: Phase III, randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma. Society for Melanoma Research Congress San Francisco, CA, USA","author":"Carvajal"},{"key":"key-10.1136\/bjophthalmol-2016-309034-66","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-67","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00008390-200508000-00003","article-title":"Immunohistochemical expression of phospho-Akt in uveal melanoma","volume":"15","author":"Saraiva","year":"2005","journal-title":"Melanoma Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/1535-7163.MCT-12-1020","article-title":"Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death","volume":"12","author":"Ambrosini","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key-10.1136\/bjophthalmol-2016-309034-70","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/1535-7163.MCT-12-0121","article-title":"Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC\/Erk1\/2 and PKC\/NF-kappaB pathways","volume":"11","author":"Wu","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key-10.1136\/bjophthalmol-2016-309034-71","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1038\/onc.2013.418","article-title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"key-10.1136\/bjophthalmol-2016-309034-72","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1167\/iovs.03-1196","article-title":"c-Kit\u2013dependent growth of uveal melanoma cells: a potential therapeutic target?","volume":"45","author":"All-Ericsson","year":"2004","journal-title":"Invest Opthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2016-309034-73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","article-title":"Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies","volume":"65","author":"Gerber","year":"2005","journal-title":"Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-74","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archopht.124.10.1428","article-title":"Vascular endothelial growth factor a in eyes with uveal melanoma","volume":"124","author":"Missotten","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-75","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1167\/iovs.09-4755","article-title":"Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma","volume":"51","author":"Yang","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.1136\/bjophthalmol-2016-309034-76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/CMR.0000000000000125","article-title":"The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma","volume":"25","author":"Moser","year":"2015","journal-title":"Melanoma Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-77","doi-asserted-by":"crossref","first-page":"Abstract 9057","DOI":"10.1200\/jco.2013.31.15_suppl.9057","article-title":"BEVATEM: Phase II study of bevacizumab (B) in combination with temozolomide (T) in patients (pts) with first-line metastatic uveal melanoma (MUM): final results","volume":"31","author":"Piperno-Neumann","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-78","doi-asserted-by":"crossref","first-page":"Abstract 9094","DOI":"10.1200\/jco.2013.31.15_suppl.9094","article-title":"Activity of cabozantinib in metastatic uveal melanoma: updated results from a phase II randomized discontinuation trial (RDT)","volume":"31","author":"Daud","year":"2013","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-79","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"key-10.1136\/bjophthalmol-2016-309034-80","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-81","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.4049\/jimmunol.165.12.7308","article-title":"Adoptive T cell immunotherapy of human uveal melanoma targeting gp100","volume":"165","author":"Sutmuller","year":"2000","journal-title":"J Immunol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-82","doi-asserted-by":"crossref","first-page":"953","DOI":"10.12659\/MSM.890496","article-title":"Clinical application of adoptive T cell therapy in solid tumors","volume":"20","author":"Zang","year":"2014","journal-title":"Med Sci Monit"},{"key":"key-10.1136\/bjophthalmol-2016-309034-83","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archopht.119.5.670","article-title":"Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15","volume":"119","author":"Collaborative Ocular Melanoma Study Group","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1245\/s10434-009-0677-0","article-title":"Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy","volume":"17","author":"Ripley","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-85","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2214\/AJR.07.2675","article-title":"Hepatic arterial chemoembolization for management of metastatic melanoma","volume":"190","author":"Sharma","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-87","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cncr.28480","article-title":"Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options","volume":"120","author":"Agarwala","year":"2014","journal-title":"Cancer"},{"key":"key-10.1136\/bjophthalmol-2016-309034-88","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.seminoncol.2010.03.014","article-title":"Locoregional management of hepatic metastasis from primary uveal melanoma","volume":"37","author":"Sato","year":"2010","journal-title":"Semin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1245\/s10434-013-3304-z","article-title":"Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit","volume":"21","author":"Olofsson","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-90","doi-asserted-by":"crossref","first-page":"Abstract LBA8512","DOI":"10.1200\/jco.2010.28.18_suppl.lba8512","article-title":"A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma","volume":"28","author":"Pingpank","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-91","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","article-title":"Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients","volume":"36","author":"Klingenstein","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-92","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/bjo.86.3.333","article-title":"Mode of presentation and time to treatment of uveal melanoma in Finland","volume":"86","author":"Eskelin","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-93","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ophtha.2014.08.046","article-title":"Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2016-309034-94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2005.02.2418","article-title":"High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma","volume":"24","author":"Abdel-Rahman","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-95","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0002-9440(10)64817-1","article-title":"Deregulation of the Rb and p53 pathways in uveal melanoma","volume":"157","author":"Brantley","year":"2000","journal-title":"Am J Pathol"},{"key":"key-10.1136\/bjophthalmol-2016-309034-96","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"key-10.1136\/bjophthalmol-2016-309034-97","first-page":"3660","article-title":"Disruption of the MMAC1\/PTEN gene by deletion or mutation is a frequent event in malignant melanoma","volume":"57","author":"Guldberg","year":"1997","journal-title":"Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-98","first-page":"5269","article-title":"Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma","volume":"54","author":"Ohta","year":"1994","journal-title":"Cancer Res"},{"key":"key-10.1136\/bjophthalmol-2016-309034-99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/13816819609057868","article-title":"Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16)","volume":"17","author":"Singh","year":"1996","journal-title":"Ophthalmic Genet"},{"key":"key-10.1136\/bjophthalmol-2016-309034-100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ctrv.2007.12.002","article-title":"Targeted therapy for uveal melanoma","volume":"34","author":"Triozzi","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"key-10.1136\/bjophthalmol-2016-309034-101","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/01.LAB.0000101732.89463.29","article-title":"Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea","volume":"83","author":"Weber","year":"2003","journal-title":"Lab Invest"},{"key":"key-10.1136\/bjophthalmol-2016-309034-102","doi-asserted-by":"crossref","first-page":"e18257","DOI":"10.1371\/journal.pone.0018257","article-title":"A melanoma molecular disease model","volume":"6","author":"Vidwans","year":"2011","journal-title":"PLoS ONE"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2016-309034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T04:41:48Z","timestamp":1657168908000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2016-309034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/bjophthalmol-2016-309034"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309034","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,29]]}}}